171 results
Page 2 of 9
8-K
EX-10.2
uoq2s7l5st
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
r5biqpmjpbrh9onca7ij
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
mxwy bso0g
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-23.2
a6xt4
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-23.1
nb4mhpmxitmzrjh3y
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
EX-23.1
2lpmcml7
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
EX-23.2
da5evb
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
2ga5sklqe85 3z
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
w0g93wck5zo6 hcvf5x
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
190h5n0m8t58300irie7
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-10.1
1r0i8c wqyship
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
vejyyempj1 qkv62ci2v
28 Apr 22
Prospectus supplement for primary offering
8:09am